Literature DB >> 2573242

Pharmacological data of the atypical neuroleptic compound melperone (Buronil).

E G Christensson1.   

Abstract

Based on the non-cataleptic properties, the weak affinity for D2 receptors and the inability to induce DA receptor supersensitivity after both acute and repeated administration, melperone may be characterized as an atypical neuroleptic drug. This indicates a weak effect of melperone on striatal DA neurotransmission. On the other hand melperone is potent in blocking amphetamine induced locomotion, exploratory behaviour, L-Dopa induced jumping and aggression suggesting a limbic mode of action. The effect on limbic DA neurotransmission together with an antiadrenergic and 5-HT modulating action may explain the antipsychotic effect and the low incidence of extrapyramidal side effects observed during treatment with melperone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573242     DOI: 10.1111/j.1600-0447.1989.tb06430.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  2 in total

1.  Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone.

Authors:  Michael D Köhnke; Ulrich Lutz; Gerlinde Wiatr; Frank Schwärzler; Bastian Weller; Klaus Schott; Gerhard Buchkremer
Journal:  Eur J Clin Pharmacol       Date:  2006-03-14       Impact factor: 2.953

2.  Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.

Authors:  Gudrun Hefner; Stefan Unterecker; Mohamed E E Shams; Margarete Wolf; Tanja Falter; Ekkehard Haen; Christoph Hiemke
Journal:  J Neural Transm (Vienna)       Date:  2015-05-05       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.